Join to View Full Profile
7000 SW 62nd Ave Ste 600South Miami, FL 33143
Phone+1 305-830-0719
Dr. Isikwei is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Emasenyie Isikwei, MD, is a family medicine specialist located in South Miami, FL, who completed her medical education at Windsor University School of Medicine in 2010. She has contributed to multiple publications primarily focused on pediatric oncology, including studies on inhibitors and optimal dosing strategies for recurrent or refractory solid tumors in children. Her research has been published in well-regarded journals such as the European Journal of Cancer, Pediatric Blood & Cancer, and Clinical Cancer Research, with several of her studies being cited by other academics.
Education & Training
Windsor University School of MedicineClass of 2010
Certifications & Licensure
FL State Medical License 2024 - 2026
Publications & Presentations
PubMed
- 1 citationsPhase 1 study of NEDD8 activating enzyme inhibitor pevonedistat in combination with chemotherapy in pediatric patients with recurrent or refractory solid tumors (ADVL1...Jennifer H Foster, Joel M Reid, Charles Minard, Sarah Woodfield, Kristina Z Denic
European Journal of Cancer. 2024-09-01 - A phase 1 trial utilizing a pharmacokinetic endpoint to determine the optimal dose of ramucirumab in children and adolescents with relapsed or refractory solid tumors,...Kristy L Pilbeam, Kamnesh Pradhan, James Croop, Charles G Minard, Xiaowei Liu
Pediatric Blood & Cancer. 2024-03-01 - 2 citationsFeasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712.Katherine Tarlock, Xiaowei Liu, Charles G Minard, Emasenyie A Isikwei, Joel M Reid
Pediatric Blood & Cancer. 2023-12-01
Journal Articles
- Risk Factors for Hypogammaglobulinemia in Chronic Lymphocytic Leukemia Patients Treated with Anti-Cd20 Monoclonal Antibody-Based TherapiesMcNulty, Caitlin M., Emasenyie A. Isikwei, Pragya Shrestha, Melissa R. Snyder, Brian F. Kabat, Kari G. Rabe, Susan L. Slager, Sameer A. Parikh, and Avni Y. Joshi, Journal of Hematopathology, 10/1/2020
Abstracts/Posters
- Phase 1 study of pevonedistat (MLN4924) a NEDD8 activating enzyme inhibitor, in combination with temozolomide (TMZ) and irinotecan (IRN) in pediatric patients with rec...Jennifer Foster, Joel M. Reid, Charles G. Minard, Emasenyie Isikwei, Xiaowei Liu, Stacey L. Berg, Sarah Garrett Injac, Elizabeth Fox, Brenda Weigel, 2021 ASCO Annual Meeting, Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021) 10019-10019
- Feasibility of Pevonedistat Combined with Azacitidine, Fludarabine, Cytarabine in Pediatric Relapsed/Refractory AML: Results from COG ADVL1712Katherine Tarlock, Xiaowei Liu, Charles G. Minard, Sarah Menig, Joel M. Reid, Emasenyie Isikwei, Sharon Bergeron, Terzah M Horton, Elizabeth Fox, Brenda Weigel, Todd M..., 2021 ASCO Annual Meeting, Journal of Clinical Oncology, 5/28/2021
- Prediction of drug disposition using physiologically based pharmacokinetic (PBPK) modeling approach: Venlafaxine Extended Release formulationEmasenyie Isikwei, M.D., Julie Cunningham, Pharm.D., R.Ph, Carrie Krieger, Pharm.D., R.Ph, Joel Reid, Ph.D, ASCPT 2020, American Society for Clinical Pharmacology and Therapeutics, 9/2020
- Join now to see all
Grant Support
- NIH T32 Training GrantNIH2018–2020
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
